Clostridioides difficile (C. difficile) is a leading cause of illness and death, especially for frail and hospitalized Americans. Now, a new study suggests that the leading antibiotic used to fight it ...

Please provide your email address to receive an email when new articles are posted on . However, this finding did not reach statistical significance, the researchers noted. “This is the first ...

C. difficile infection recurrence rates were numerically lower with vancomycin than with placebo, though the difference was not significant. However, the results could be clinically meaningful, an ...

Fecal microbiota transplant was noninferior to vancomycin as the initial treatment for C. diff in a randomized, open-label trial. Transplant showed slightly higher cure rates without recurrence and ...

University of Wisconsin–Madison–led researchers report lower yet statistically non-significant recurrence of Clostridioides difficile (C. diff) among adults given low-dose oral vancomycin during ...

Please provide your email address to receive an email when new articles are posted on . Clinicians should carefully monitor patients with inflammatory bowel disease and comorbid Clostridioides ...

Thirty-day all-cause mortality among patients with severe Clostridium difficile infection (CDI) was significantly lower when vancomycin was used as first-line therapy compared with metronidazole, ...

April 4, 2012 (London, United Kingdom) — Fidaxomicin (Dificid, Optimer Pharmaceuticals) treatment was superior to vancomycin for initial cure, recurrence, and sustained response, according to a ...

Researchers at the University of Sheffield have discovered how a hospital superbug Clostridioides difficile (C.diff) can rapidly evolve resistance to vancomycin, the frontline drug used in the UK ...